Business Wire

Temenos Welcomes Industry Leaders and Rising Stars of Fintech to Make Banking Better, Together at TCF Online 2021

12.5.2021 09:30:00 EEST | Business Wire | Press release

Share

Temenos (SIX: TEMN), the banking software company, today announced that 10,000 business leaders and technologists will come together on 26 - 27 May at TCF Online 2021, the flagship event in banking. The two-day interactive, online-only event will feature keynotes from PayPal, Barclays and Varo, plus over 50 live and on-demand sessions and 50 industry speakers inspired by a shared mission to make banking better, together. Register for this free to attend event.

Powered by new technologies such as Cloud, AI and SaaS, banks of all sizes can deliver customer experiences that are better, faster and smarter. They can also achieve hyper-efficient cost models to deliver more value to their customers and leverage open ecosystems to enhance and extend their offering. At TCF Online 2021, Temenos will unveil game-changing innovations enabling banks to simplify their operations, innovate and collaborate at speed and digitally transform faster than ever before.

At TCF Online 2021, attendees from over 150 countries will also hear from some of the most influential industry experts in the financial sector, including:

  • Ryan Prichard, VP, CTO of Global Credit, PayPal, on the latest innovations in payments, including how PayPal is disrupting the market with its new buy now, pay later product enabled by Temenos technology.
  • Ashok Vaswani, CEO of Consumer Banking and Payments, Barclays, on the importance of banks being purpose-led and playing a greater role in the economy and society in a post-pandemic world.
  • Colin Walsh, Founder and CEO, Varo, a year on after making history as the first fintech in the U.S. to obtain a national banking license, on making banking more accessible and inclusive for all.
  • Jim Marous, co-publisher of The Financial Brand and top 100 influencer, on how banks can humanize their customer experience in a digital world and joining him on the virtual stage, Chris Parker, Co-CEO of Partners Federal Credit Union.
  • Eric Purdum, General Manager, DXC on its collaboration with Temenos and accelerating the digital transformation for large tier-1 banks.
  • David Hornery, Co-CEO and Co-Founder, Judo, on the future for challenger banks and Judo’s unique approach to the SME market in Australia.
  • Barri Maggott, CEO, Curo Fund Services, on the digital transformation journey in funds administration.
  • And Max Chuard, CEO of Temenos, on the once-in-a-generation opportunity digital presents for banking, unveiling Temenos’ latest innovations in cloud and AI that will propel the industry forward.

Max Chuard, CEO, Temenos, said: “The urgency for change in banking has never been greater. Consumers and business customers demand and expect fast, frictionless, personalized experiences. Covid-19 has accelerated the trend towards digital banking and new technologies such as Cloud, AI and SaaS make the business case for transformation compelling. Yet while challengers are innovating and launching rapidly on modern technology stacks, legacy systems are still holding banks back. Temenos technology gives all banks the freedom, agility and speed to innovate and adapt to changing customer behavior, business and regulatory change. At TCF Online 2021, our community of thousands will hear about the latest innovations and how together we will make banking better.”

TCF Online brings the key announcements, customer insights and latest software demonstrations from Temenos. To register for this free-to-attend event, visit www.temenos.com/events/tcf-online-2021.

– Ends –

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.

For more information, please visit www.temenos.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email : press@temenos.com

Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye